Do You Need to Stop Your GLP-1 Before Surgery?

Because GLP-1 medications slow how fast your stomach empties, and anesthesia assumes an empty stomach.

When you go under general anesthesia or deep sedation, the reflexes that normally protect your airway switch off. If there is still food or liquid sitting in your stomach, it can flow backward up the esophagus and be inhaled into the lungs. This is pulmonary aspiration, and while it is rare, it can cause a serious chemical pneumonitis. Standard fasting rules — no solid food for 8 hours, no clear liquids for 2 hours — exist entirely to prevent it.

GLP-1 medications work partly by delaying gastric emptying, which is a feature, not a bug: it is one of the reasons you feel full longer and eat less. Our explainer on [how GLP-1 medications work](/blog/how-glp1-medications-work-mechanism-explained) walks through the full mechanism. But it means the standard 8-hour fast may not reliably empty the stomach in someone on a weekly GLP-1.

The alarm was raised by case reports starting around 2022 — patients who had fasted appropriately but were found on endoscopy to have significant retained food. Anesthesiologists began cancelling procedures on the day of surgery, sometimes after patients had already taken time off work and completed a bowel prep.

That is the tension the guidance has been trying to resolve: a real but uncommon safety concern on one side, and on the other the cost of cancelled procedures and interrupted treatment for a medication that people need for diabetes control and cardiometabolic risk reduction.

In June 2023, the American Society of Anesthesiologists issued consensus-based guidance that was deliberately conservative.

For patients on daily-dosed GLP-1 agonists, it advised holding the medication on the day of the procedure. For patients on weekly-dosed agonists — which covers semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — it advised holding the dose for a full week before the procedure. It also suggested that if a patient had any gastrointestinal symptoms such as nausea, vomiting, bloating, or abdominal pain, the procedure should be delayed.

The ASA was explicit that this was consensus opinion, not evidence-based guideline — there simply were not trials to draw on. It was a reasonable precaution issued in the face of genuine uncertainty and a rapidly growing number of patients on these drugs.

In practice, it created problems. Holding a weekly GLP-1 for seven days means missing an entire dose, which for someone with type 2 diabetes can mean a meaningful loss of glycemic control right before surgery — and poor glucose control is itself an independent risk factor for surgical complications and wound infection. It also meant that patients whose stomachs were perfectly empty were having procedures cancelled, and that some patients simply stopped taking their medication altogether around a procedure and never restarted.

The field spent the following 18 months gathering actual data. What emerged was more reassuring than the initial alarm suggested.

The blanket hold was replaced with individualized risk assessment, and the emphasis shifted from stopping the drug to changing what you eat.

In October 2024, five organizations published joint guidance together: the American Society of Anesthesiologists, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons (Kindel TL, et al., Clin Gastroenterol Hepatol, 2024).

Their central conclusion: most patients can safely continue GLP-1 therapy before a procedure. Rather than holding the medication, the primary mitigation is a 24-hour clear liquid diet before the procedure — which addresses the actual problem (solid food retained in the stomach) far more directly than skipping a dose.

The guidance also moved the decision into shared decision-making between the patient, the proceduralist, the anesthesia team, and the prescribing clinician. It recommends assessing each patient for factors that increase the risk of delayed gastric emptying, and reserving a medication hold for those patients.

There is one more useful piece: the guidance notes that when there is residual concern on the day of the procedure, gastric ultrasound can be used to look directly at whether the stomach is empty, rather than guessing. Not every center has this capability, but it is becoming more common.

Importantly, the authors again labeled this guidance, not an evidence-based guideline — the underlying research is still developing. Individual hospitals may have their own protocols that differ, and those protocols govern your care.

The 2024 guidance identifies patients more likely to have retained gastric contents, and these are the people for whom holding the medication is still worth considering.

The factors that raise concern cluster into two groups. The first is where you are in your dose schedule. If you are in the escalation phase — still stepping the dose up — your gut has not yet adapted, and delayed emptying tends to be most pronounced. Someone who has been stable on a maintenance dose for a year is in a different situation than someone who just moved from 0.5 mg to 1 mg last week. The highest doses also carry more effect on gastric motility.

The second is whether you currently have symptoms. Active nausea, vomiting, abdominal distension, or significant early satiety all suggest your stomach is not emptying well right now. If you are experiencing [ongoing GLP-1 nausea](/blog/glp1-nausea-why-it-happens-and-how-to-ease-it), that is directly relevant information for your anesthesia team.

Other factors that increase risk include known gastroparesis (whether from long-standing diabetes or another cause), significant gastroesophageal reflux disease, use of other medications that slow the gut such as opioids or anticholinergics, and procedures that themselves carry higher aspiration risk.

The important shift is that this is now a *conversation* rather than a rule. Two people on the same 2.4 mg dose of semaglutide can end up with completely different plans depending on their symptoms, their procedure, and their diabetes status — and that is the point.

Disclose early and be specific. The details matter more than the fact.

Bring five pieces of information to your pre-operative appointment. The exact drug and brand — semaglutide and tirzepatide are different molecules with somewhat different effects on gastric emptying, and the team needs to know which. Your current dose and how long you have been on it. The day of the week you inject, so the team can time the procedure relative to your dose if they want to. Whether you have escalated recently — a dose increase in the past 4 weeks is meaningful. Whether you are having any GI symptoms right now, honestly, including bloating and feeling full quickly.

Also say why you are on it. If your GLP-1 is prescribed for type 2 diabetes, holding it is a bigger decision than if it is prescribed for weight management alone, because glycemic control affects surgical outcomes. This is exactly why the prescribing clinician is included in the shared decision-making model.

Mention compounded versions if that is what you take. Compounded semaglutide may have different concentration and dosing than the brand product, and your team should not have to guess — our guide on [compounded versus brand GLP-1s](/blog/compounded-vs-brand-glp1-whats-the-difference) explains the differences.

One more thing: ask what their protocol is. Hospitals adopt guidance at different speeds, and some still follow the 2023 hold rule. Knowing this two weeks out gives you time to plan around a missed dose rather than discovering it the night before.

Follow their instruction. Then plan for the gap.

Institutional protocols exist for legal and operational reasons, and the anesthesiologist assessing you on the day has final authority over anesthetic safety. Arguing with the pre-op nurse using a journal article is not a winning strategy, and the 2024 document is explicitly guidance rather than a mandate.

What you can do is manage the consequences. If you have type 2 diabetes, contact your prescriber as soon as you know a hold is planned — you may need a bridging plan for blood sugar during the gap, and this is not something to improvise. If you take a GLP-1 for weight management, missing one weekly dose is generally not a clinical problem, but expect appetite to return noticeably in the second half of the week and expect some fluid weight to come back. That is normal and not a real regain.

When you restart, ask whether to resume at your usual dose or step down. If the gap ends up longer than a couple of weeks — say, a complicated recovery — many prescribers will re-titrate from a lower dose, because gut tolerance fades and jumping straight back to a high dose often means a week of nausea. That same logic applies to any extended interruption, which we cover in [how to taper or restart a GLP-1](/blog/stopping-glp1-weight-regain-and-how-to-taper-safely).

And if you can influence timing at all, scheduling a non-urgent procedure when you are on a stable maintenance dose rather than mid-escalation makes the whole conversation simpler.

Yes — and endoscopy is actually where much of the original concern came from.

The 2024 guidance was co-authored by the American Gastroenterological Association and the Society of American Gastrointestinal and Endoscopic Surgeons precisely because these procedures involve sedation and because gastroenterologists were the ones directly *seeing* retained food during upper endoscopies. That is where the case reports originated.

For a colonoscopy, there is a built-in advantage: the bowel prep already requires a clear liquid diet for roughly 24 hours beforehand, which is exactly the mitigation the guidance recommends. In practice, someone on a GLP-1 having a standard colonoscopy with a full prep has largely already met the requirement. Some centers still add an extra day of clear liquids for GLP-1 users.

For an upper endoscopy (EGD), the picture is different, because there is no prep requiring clear liquids. This is where an extended clear liquid period is most likely to be requested, and where day-of cancellations were most common under the old rules.

One practical note that trips people up: your GLP-1 can also affect the *quality* of a bowel prep, since slowed gut transit can mean the prep works less completely. If your prep result is poor, the procedure may need repeating — so follow the prep instructions exactly, and tell the endoscopy unit about the medication when you book, not when you arrive.

Minor procedures under local anesthetic without sedation — a skin biopsy, a dental filling, cataract surgery with topical anesthesia — do not raise this concern at all, because your airway reflexes stay intact.